This randomized, crossover study aims to investigate the intradialytic kinetics of selected cardiac biomarkers in patients with end-stage renal disease treated with dialysis. The cardiac biomarkers of interest include high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, brain natriuretic peptide, and a novel cardiac biomarker named secretoneurin. In 24 patients treated with maintenance hemodialysis, the study will compare high-flux hemodialysis (HD) with post-dilution hemodiafiltration (HDF) to investigate: * Baseline concentrations and week-to-week plasma variations of the cardiac biomarkers. * Changes in the plasma concentrations of the cardiac biomarkers during high-flux HD and post-dilution HDF. * Dialyzer clearance of the cardiac biomarkers in high-flux HD and post-dilution HDF. * Adherence of the cardiac biomarkers to the dialyzer membrane. * Concentrations of the cardiac biomarkers 30 minutes post-dialysis to investigate a potential rebound effect. Additionally, a sub-study of 24 patients treated with peritoneal dialysis will investigate the baseline concentrations and week-to-week plasma variations of the same cardiac biomarkers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in the cardiac biomarkers from baseline to during and after high-flux hemodialysis and post-dilution hemodiafiltration.
Timeframe: Before the start of a dialysis session; after 10, 30, 60, 120, 180, and 240 minutes of dialysis; and 5-30 min. after dialysis cessation.